CDKN2A and neoplasm: DKC1-high tumors exhibited higher rates of activating-mutations or copy gains of the oncogenic drivers (PIK3CA, MYC, SOX17, PPP2RA1, ERBB2, CCNE1, FGFR3 and CTNNB1) whereas more frequent inactivating mutations or copy loss of the tumor suppressors (TP53, PTEN, CDKN2A, and FBXW7) (Figure 6G right).